Drug Profile
SDZ GLC 756
Alternative Names: GLC 756Latest Information Update: 12 Oct 2005
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiglaucomas
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 03 Oct 2000 Discontinued - Phase-I for Glaucoma in Switzerland (Ophthalmic)
- 12 Jun 1997 New profile
- 12 Jun 1997 Phase-I clinical trials for Glaucoma in Switzerland (Ophthalmic)